Researchers have developed a new pair of agents that show exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies. The agents, which target prostate-specific membrane antigen (PSMA), can be easily and economically synthesized without specialized equipment. This research was presented at the Society of Nuclear Medicine and Molecular Imaging’s 2020 Annual Meeting on July 11-14, 2020.
- UMD-led study shows fear and anxiety share same bases in brain
- Patients who had more severe covid-19 may be the best donors for convalescent plasma therapy
- Astrophysics team lights the way for more accurate model of the universe
- Tropical cyclones moving faster in recent decades
- Untreated sleep apnea is associated with flu hospitalization